Dapagliflozin 10mg Tab
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Heart Failure
Conditions
Heart Failure
Trial Timeline
Nov 8, 2023 → Mar 1, 2026
NCT ID
NCT05741658About Dapagliflozin 10mg Tab
Dapagliflozin 10mg Tab is a approved stage product being developed by AstraZeneca for Heart Failure. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05741658. Target conditions include Heart Failure.
What happened to similar drugs?
20 of 20 similar drugs in Heart Failure were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05741658 | Approved | Recruiting |
| NCT04794517 | Phase 2 | Completed |
Competing Products
20 competing products in Heart Failure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-0184 | Moderna | Phase 1 | 0 |
| IV diuretic | Nuwellis | Pre-clinical | 16 |
| IV Loop Diuretics | Nuwellis | Pre-clinical | 23 |
| Stepped pharmacologic care | Nuwellis | Phase 3 | 30 |
| IV Loop Diuretics (LD) | Nuwellis | Pre-clinical | 8 |
| TRV120027 + Normal Saline | Trevena | Phase 1 | 19 |
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 25 |
| TRV120027 + Placebo | Trevena | Phase 1/2 | 22 |
| Ilofotase alfa + Placebo | AM-Pharma | Phase 2 | 25 |
| INXN-4001 | Precigen | Phase 1 | 23 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 29 |
| SGLT2i, beta blocker, ARNI, MRA, MTD | Eli Lilly | Approved | 43 |
| Pactimibe, CS-505 | Daiichi Sankyo | Phase 2 | 35 |
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 43 |
| olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil | Daiichi Sankyo | Phase 3 | 32 |
| Olmesartan | Daiichi Sankyo | Phase 3 | 40 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 35 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 22 |
| Regadenoson | Astellas Pharma | Phase 1 | 29 |
| Advagraf + Prograf | Astellas Pharma | Phase 2 | 35 |